The role of monocytes/macrophages in TCR-ζ chain downregulation and apoptosis of T lymphocytes in malignant pleural effusions

Journal of Biological Regulators and Homeostatic Agents

Volumn 18, Issue 1, 2004, Pages 26-32

  Sikora, Jan ^a   Dworacki, G ^a   Giersz, R ^b   Zeromski, J ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Oncology Department   (Poland)

Author keywords

Apoptosis; Malignant pleural effusions; T lymphocytes; TCR chain

Indexed keywords

CD14 ANTIGEN; CD3 ANTIGEN; CELL MARKER; CYTOKERATIN; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE ZETA RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MACROPHAGE; MONOCYTE; NICK END LABELING; PLEURA EFFUSION; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; T LYMPHOCYTE; TUMOR CELL;

EID: 4444339448     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Strand S, Hofmann WJ, Hug H et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells. A mechanism of immune evasion? Nat Med 1996; 2: 1361-6.
2. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: A molecular mechanism of tumor immune privilege. Mol Med 1997; 3: 294-300.
3. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas mediated T-cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-82.
4. Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Takahashi H. Expression of Fas Ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 1997; 94: 6420-5.
5. Gastman BR, Atarashi Y, Reichert TE, et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck and it promots apoptosis of T lymphocytes. Cancer Res 1999; 59: 5356-64.
6. Staveley-O'Carroll K, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci USA 1998: 95: 1178-83.
7. Esche C, Lokshin A, Shurin GV, et al. Tumor's other immune targets: Dendritic cells. J Leukoc Biol 1999; 66: 336-44.
8. Goto S, Sato M, Kaneko R, Itoh M, Sato S, Takeuchi S. Analysis of Th1 and Th2 cytokine production by peripheral cells as a parameter of immunological dysfunction in advanced cancer patients. Cancer Immunol Immunother 1999; 48: 435-42.
9. Fox FE, Capocasale RJ, Ford HC, Lamb RJ, Moore JS, Nowell PC. Transforming growth factor-β inhibits human T cells proliferation through multiple targets. Lymphokine Cytokine Res 1992; 11: 299-305.
10. Tada T, Ohzeki S, Utsumi K, et al. Transforming growth factor-β- induced inhibition of T-cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol 1991; 146: 1077-82.
11. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon-γ production by suppressing natural killer cell stimulatory factor /IL-12 synthesis in accessory cells. J Exp Med 1993; 178: 1041-8.
12. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147: 3815-22.
13. Lopez DM, Lopez-Cepero M, Watson GA, Ganju A, Sotomayor E, Fu YX. Modulation of the immune system by mammary tumor-derived factors. Cancer Invest 1991; 9: 643-53.
14. van der Pouw Kraan TC, Boeije LC, Smeenk RJ, Wijdenes J, Aarden LA. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med 1995; 181: 775-9.
15. Uotila P. The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer. Cancer Immunol Immunother 1996; 43: 1-9.
16. Nagata S, Goldstein P. The Fas death factor. Science 1995; 267: 1449-56.
17. Kono K, Salazar-Onfray F, Petersson M, et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal transduction ζ molecules and inhibits tumor-specific T cell and natural killer cell-mediated cytotoxicity. Eur J Immunol 1996; 26: 1308-13.
18. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alterations in signal transuding molecules in T lymphocytes from tumor-bearing mice. Science 1992; 258: 1795-8.
19. Saito T, Kuss I, Dworacki G, Gooding W, Johnson JT, Whiteside TL. Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin Cancer Res 1999; 5: 1263-73.
20. Rabinowich H, Suminami Y, Reichert TE, et al. Expression of cytokine genes or proteins and signalling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer 1996; 68: 276-84.
21. Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC, Whiteside TL. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of TcR in tumor associated lymphocytes. J Clin Invest 1998; 101: 2579-88.
22. Dworacki G, Meidenbauer N, Kuss I, et al. Decreased ζ chain expression and apoptosis in CD3+ peripheral blood lymphocytes of patients with melanoma. Clin Cancer Res 2001; (Suppl.): S947-57.
23. Reichert TE, Day R, Wagner EM, Whiteside TL. Absent of low expression of the ζ chain in T cells at the tumor site correlates with the poor survival in patients with oral carcinoma. Cancer Res 1998; 58: 5344-7.
24. Rabinowich H, Banks M, Reichert TE, Logan TF, Kirkwood JM, Whiteside TL. Expression and activity of signalling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after IL-2 therapy. Clin Cancer Res 1996; 2: 1263-74.
25. lck in T-cell infiltrating human renal cell carcinoma. Cancer Res 1993; 53: 5613-6.
26. Maccalli C, Pisarra P, Vegetti C, Sensi M, Parmiani G, Anichini A. Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions. J Immunol 1999; 15: 6912-23.
27. Aoe T, Okamoto Y, Saito T. Activated macrophages induce structural abnormalities of T-cell receptor-CD3 complex. J Exp Med 1995; 181: 1881-6.
28. Otsuji M, Kimura Y, Aoe T, Okamoto Y, Saito T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci USA 1996; 93: 13119-24.
29. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 2001; 61: 4756-60.
30. Gastman BR, Johnson DE, Whiteside TL, Rabinowich H. Caspase mediated degradation of TCR-ζ chain. Cancer Res 1999; 59: 1422-7.